Cargando…
NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION
BACKGROUNDS: Primary central nervous system lymphoma (PCNSL) frequently causes severe damage of activities of daily living (ADL) and neurocognitive function (NCF) due to extensive brain infiltration, necessitating their appropriate assessment and measures even in clinical practice. Since few studies...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213283/ http://dx.doi.org/10.1093/noajnl/vdz039.137 |
_version_ | 1783531770656849920 |
---|---|
author | Taku, Mikiko Kobayashi, Keiichi Yamagishi, Yuki Saito, Kuniaki Shimada, Daisuke Matsumoto, Yoshie Kikuchi, Hana Yamada, Shin Shiokawa, Yoshiaki Nagane, Motoo Okajima, Yasutomo |
author_facet | Taku, Mikiko Kobayashi, Keiichi Yamagishi, Yuki Saito, Kuniaki Shimada, Daisuke Matsumoto, Yoshie Kikuchi, Hana Yamada, Shin Shiokawa, Yoshiaki Nagane, Motoo Okajima, Yasutomo |
author_sort | Taku, Mikiko |
collection | PubMed |
description | BACKGROUNDS: Primary central nervous system lymphoma (PCNSL) frequently causes severe damage of activities of daily living (ADL) and neurocognitive function (NCF) due to extensive brain infiltration, necessitating their appropriate assessment and measures even in clinical practice. Since few studies have focused on the changes in the level of ADL and NCF in the course of PCNSL treatment, we retrospectively analyzed the effect of initial treatment of PCNSL in view of ADL and NCF. METHODS: Among 55 patients (13 male/9 female) with newly-diagnosed PCNSL treated in our institution from January 2014 to June 2019, 22 were evaluated with both ADL and NCF. Remission induction therapies consisted of high-dose methotrexate alone (two patients), R-MPV (rituximab, methotrexate, procarbazine, and vincristine)(17 patients), and R-MPV+radiaotherapy (three patients), according to the patients’ conditions. Rehabilitation staffs intervened from the beginning, providing specific exercises and periodically evaluating scores of Karnofsky Performance Status (KPS) and Mini Mental State Examination (MMSE). RESULTS: Mean age was 68.4 yo (range 34 to 85). After induction therapies, there were 11 complete responses (CRs), eight partial responses (PRs), and three progressive diseases (PDs). Both KPS and MMSE scores improved after induction therapy, from median 70 (40–90) to 80 (50–90), and from 24 (0–30) to 27(0–30), respectively. Among three patients who underwent RT, MMSE declined in two (one CR/one PR). CONCLUSIONS: Case-adjusted induction therapies resulted in significant radiographical responses, and the longitudinal evaluation of ADL and NCF by rehabilitation staffs could validate their maintenance or improvement over time through effective treatments and early rehabilitation intervention. However, three was difficulty in assessing patients with higher brain dysfunction such as aphasia and social adjustment disorder. Further study is needed to include more patients and to explore more appropriate evaluation batteries and timings during and after completion of induction therapy for PCNSL. |
format | Online Article Text |
id | pubmed-7213283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72132832020-07-07 NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION Taku, Mikiko Kobayashi, Keiichi Yamagishi, Yuki Saito, Kuniaki Shimada, Daisuke Matsumoto, Yoshie Kikuchi, Hana Yamada, Shin Shiokawa, Yoshiaki Nagane, Motoo Okajima, Yasutomo Neurooncol Adv Abstracts BACKGROUNDS: Primary central nervous system lymphoma (PCNSL) frequently causes severe damage of activities of daily living (ADL) and neurocognitive function (NCF) due to extensive brain infiltration, necessitating their appropriate assessment and measures even in clinical practice. Since few studies have focused on the changes in the level of ADL and NCF in the course of PCNSL treatment, we retrospectively analyzed the effect of initial treatment of PCNSL in view of ADL and NCF. METHODS: Among 55 patients (13 male/9 female) with newly-diagnosed PCNSL treated in our institution from January 2014 to June 2019, 22 were evaluated with both ADL and NCF. Remission induction therapies consisted of high-dose methotrexate alone (two patients), R-MPV (rituximab, methotrexate, procarbazine, and vincristine)(17 patients), and R-MPV+radiaotherapy (three patients), according to the patients’ conditions. Rehabilitation staffs intervened from the beginning, providing specific exercises and periodically evaluating scores of Karnofsky Performance Status (KPS) and Mini Mental State Examination (MMSE). RESULTS: Mean age was 68.4 yo (range 34 to 85). After induction therapies, there were 11 complete responses (CRs), eight partial responses (PRs), and three progressive diseases (PDs). Both KPS and MMSE scores improved after induction therapy, from median 70 (40–90) to 80 (50–90), and from 24 (0–30) to 27(0–30), respectively. Among three patients who underwent RT, MMSE declined in two (one CR/one PR). CONCLUSIONS: Case-adjusted induction therapies resulted in significant radiographical responses, and the longitudinal evaluation of ADL and NCF by rehabilitation staffs could validate their maintenance or improvement over time through effective treatments and early rehabilitation intervention. However, three was difficulty in assessing patients with higher brain dysfunction such as aphasia and social adjustment disorder. Further study is needed to include more patients and to explore more appropriate evaluation batteries and timings during and after completion of induction therapy for PCNSL. Oxford University Press 2019-12-16 /pmc/articles/PMC7213283/ http://dx.doi.org/10.1093/noajnl/vdz039.137 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Taku, Mikiko Kobayashi, Keiichi Yamagishi, Yuki Saito, Kuniaki Shimada, Daisuke Matsumoto, Yoshie Kikuchi, Hana Yamada, Shin Shiokawa, Yoshiaki Nagane, Motoo Okajima, Yasutomo NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION |
title | NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION |
title_full | NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION |
title_fullStr | NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION |
title_full_unstemmed | NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION |
title_short | NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION |
title_sort | nqpc-06 functional outcomes of initial treatments for patients with primary central nervous system lymphoma assessed by adl and neurocognitive function |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213283/ http://dx.doi.org/10.1093/noajnl/vdz039.137 |
work_keys_str_mv | AT takumikiko nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction AT kobayashikeiichi nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction AT yamagishiyuki nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction AT saitokuniaki nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction AT shimadadaisuke nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction AT matsumotoyoshie nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction AT kikuchihana nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction AT yamadashin nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction AT shiokawayoshiaki nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction AT naganemotoo nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction AT okajimayasutomo nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction |